title: Clinical outcomes of bioresorbable versus durable polymer-coated everolimus-eluting stents in real-world complex patients.
abstract: OBJECTIVE
  The aim of this study was to evaluate the safety and efficacy profile of new-generation, SYNERGY everolimus-eluting stents (S-EES) as compared to XIENCE everolimus-eluting stents (X-EES) with a durable polymer coating in "complex patients".
  
  
  RESULTS
  We included 2,001 consecutive patients treated with S-EES (n=400) or X-EES (n=1,601) at two Italian centres between May 2013 and May 2015. We used propensity score matching to obtain two cohorts of patients with similar baseline risk profiles. Patients were stratified according to baseline complexity based on the EVOLVE II trial exclusion criteria. The primary outcome was major adverse cardiac events (MACE), defined as the composite of all-cause death, myocardial infarction (MI), and target lesion revascularisation (TLR), at one year. Among 391 matched pairs of patients treated with S-EES or X-EES, we identified 253 (63%) as complex. At one-year follow-up, among "complex" patients, MACE rates did not differ between the S-EES and X-EES groups (9.9% vs. 9.5%, p=0.830, HR 1.04, CI: 0.72-1.48). Similarly, death, MI, and TLR, stratified for complexity, were comparable between S-EES and X-EES treated patients at one year. Of note, no definite ST was observed in either the S-EES or the X-EES cohort.
  
  
  CONCLUSIONS
  New-generation S-EES with a bioresorbable polymer coating appear to be safe and effective irrespective of patient complexity as compared to X-EES.
authors.affiliation: Cardio Center, Humanitas Research Hospital, Rozzano-Milan, Italy.
authors.forename: Marco G
authors.initials: MG
authors.lastname: Mennuni
authors.forename: Giulio G
authors.initials: GG
authors.lastname: Stefanini
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Pagnotta
authors.forename: Elton
authors.initials: E
authors.lastname: Pllaha
authors.forename: Marco
authors.initials: M
authors.lastname: Araco
authors.forename: Omar A
authors.initials: OA
authors.lastname: Meelu
authors.forename: Federica
authors.initials: F
authors.lastname: Turati
authors.forename: Bernhard
authors.initials: B
authors.lastname: Reimers
authors.forename: Gennaro
authors.initials: G
authors.lastname: Sardella
authors.forename: Patrizia
authors.initials: P
authors.lastname: Presbitero
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000379:methods; D011108:Polymers; D011474:Prosthesis Design; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D000068338:Everolimus